Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research groups

Collaborators:

Francis Szele, DPAG, University of Oxford

Chris Schofield, Chemistry, University of Oxford

James McCullagh, Chemistry, University of Oxford

Olaf Ansorge, Clinical Neurosciences, University of Oxford

Dan Tennant, Hypoxia and Metabolism, University of Birmingham

Colin Watts, Neurosurgery, University of Birmingham

Victoria Vikes, Neurosurgery, University of Birmingham

Rachel Guest, Clinical Surgery, University of Edinburgh

Emmanuelle Huillard, ICM, France

Tomoyoshi Soga, IAB, Japan

Chiara Bardella

PhD


Research Scientist

Biography

Chiara received her PhD in Cellular Science and Technologies from the Institute for Cancer Research and Treatment, University of Turin (Italy). She subsequently moved to the University of Oxford as a Postdoctoral Fellow in Professor Ian Tomlinson’s laboratory at the Wellcome Trust Centre for Human Genetics, where she developed expertise in cancer genetics and functional biology of metabolic oncogenes and tumour suppressor genes, including FH and IDH, across different cancer contexts.

In 2017, Chiara joined the Institute of Cancer and Genomic Sciences at the University of Birmingham, where in 2018, she was appointed Principal Investigator and established the Laboratory of Molecular Mechanisms Underlying Glioma Development.

Since 2023, Chiara has been a member of the Department of Oncology, where she continues her research on cellular and molecular mechanisms of gliomagenesis.

Research Summary

Chiara’s research is focused on the molecular mechanisms underlying tumour initiation and progression, with a particular interest in cancers driven by the accumulation of oncometabolites. Many gliomas show mutations in a protein called isocitrate dehydrogenase (IDH). Chiara investigates mechanisms of gliomagenesis, tumour cell identity, and metabolic vulnerabilities in a way that bridges fundamental biology and clinical need. By combining in vivo modelling, patient-derived systems, functional genomics and metabolic profiling technologies she explores how mutations in metabolic enzymes contribute to oncogenesis and how these mechanisms may be targeted therapeutically.

Key publications

Recent publications

More publications